Saturday, November 2, 2024

JUVÉDERM® VOLUMA® XC Now Nationwide for Treating Moderate to Severe Temple Hollowing

Similar articles

Subscribe Weekly Market Access News

* indicates required

Key Takeaways

  • JUVÉDERM® VOLUMA® XC, the first and only FDA-approved hyaluronic acid filler for temple hollowing, is now available across the U.S.
  • Over 85% of patients report lasting improvements up to 13 months after treatment, achieving a youthful, balanced appearance.
  • Allergan Aesthetics provides extensive provider training to ensure safe, effective results for temple augmentation.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced the national availability of JUVÉDERM® VOLUMA® XC, following FDA approval in March 2024 which is the first and only hyaluronic acid (HA) dermal filler specifically approved for treating moderate to severe temple hollowing in adults aged 21 and over. With this new indication, JUVÉDERM® VOLUMA® XC joins Allergan’s portfolio of treatments designed to restore volume and create a more youthful appearance.

Temple hollowing, a common yet overlooked sign of aging, impacts facial balance and can make the eyes and forehead appear sunken. JUVÉDERM® VOLUMA® XC offers a solution to this issue by restoring volume to the temples, providing natural-looking results that enhance overall facial harmony.

Carrie Strom, President of Allergan Aesthetics, expressed the company’s commitment to quality: “Our goal is to provide licensed providers with the advanced training needed to safely and effectively treat the temple area, just as we do with all our injectable treatments. We’re excited to see the beautiful, lasting results our customers will achieve using JUVÉDERM® VOLUMA® XC as part of a comprehensive facial rejuvenation plan.”

High Satisfaction and Long-Lasting Results for Patients Nationwide

Clinical studies have demonstrated impressive results for JUVÉDERM® VOLUMA® XC in treating temple hollowing, with more than 85% of patients reporting noticeable improvements in appearance one month after treatment. Additionally, these results were shown to last up to 13 months, offering patients a long-term solution for restoring volume and maintaining a youthful look.

Notably, 98% of patients treated with JUVÉDERM® VOLUMA® XC in clinical trials said they would recommend the procedure to a friend. Dr. Christopher Surek, a board-certified plastic surgeon, highlighted the significance of this new treatment option: “For many patients, the temple area is key to achieving a balanced and youthful appearance. JUVÉDERM® VOLUMA® XC offers immediate and natural-looking lift to the temples, making it an ideal option for subtle facial rejuvenation.”

This new indication for JUVÉDERM® VOLUMA® XC builds on the brand’s success in treating other areas of the face, such as the cheeks and chin. With six HA fillers in its collection, JUVÉDERM® remains a trusted leader in facial aesthetics, helping patients achieve their individual aesthetic goals.

Training-Led Launch for Safe and Effective Treatments

In line with its commitment to patient safety and provider education, Allergan Aesthetics has implemented a rigorous training protocol for aesthetic providers administering JUVÉDERM® VOLUMA® XC for temple hollowing. Training focuses on facial anatomy, safe injection techniques, and management of potential complications, ensuring that patients receive the best possible care and outcomes. This training is mandatory for all providers who wish to offer the new temple augmentation treatment.

Providers and patients alike can benefit from Allergan’s comprehensive Allē rewards program, which offers points and flexible payment plans for aesthetic treatments. With 7 million members and partnerships with 30,000 practices, Allē aims to empower consumers throughout their aesthetic journey, providing tools and information to help them make informed choices about their treatments.

 Temple Hollowing

You can follow our news on our Telegram, LinkedIn and Youtube accounts.

Setting a New Standard in Aesthetic Medicine

With the launch of JUVÉDERM® VOLUMA® XC for temple hollowing, Allergan Aesthetics continues to lead the field in innovative facial injectables. As the only HA filler approved for this indication, JUVÉDERM® VOLUMA® XC offers patients and providers a unique opportunity to address one of the most critical areas for facial balance and rejuvenation.

Patients interested in temple hollowing treatments are encouraged to learn more by visiting www.juvederm.com or contacting a licensed provider. By combining advanced technology, comprehensive training, and a commitment to safety, Allergan Aesthetics is redefining what is possible in aesthetic medicine, offering results that are both natural and long-lasting.

 

Resource: Abbvie, October 02, 2024


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article